Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of recombinant human N-acetylgalactosamine 4-sulfatase in mucopolysaccharidosis VI
2004-000642-21Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Jun 2004
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of galsulfase in mucopolysaccharidosis type VI (2 arms), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Change in 12-minute walk test distance. Started Jun 2004; status: completed.
02
Drugs
galsulfase
03
Conditions
mucopolysaccharidosis type VI
Beyond the preview
Go deeper on 2004-000642-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000642-21.